Innate Pharma announces trading halt of its ordinary shares on Euronext Paris
October 17, 2019 02:30 ET
|
INNATE PHARMA
Marseille, France, October 17, 2019, 8:30 AM CEST INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“Innate” or the “Company”), a French biotechnology company focused on discovering,...
Innate Pharma announces the pricing of its initial public offering on the Nasdaq global select market
October 17, 2019 01:00 ET
|
INNATE PHARMA
Marseille, France, October 17, 2019, 7:00 AM CEST INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“Innate Pharma” or the “Company”), a French biotechnology company focused on...
Innate Pharma announces launch of proposed global offering and Nasdaq listing
October 07, 2019 01:00 ET
|
INNATE PHARMA
Marseille, France, October 7, 2019, 7:00 CEST INNATE PHARMA S.A. (Euronext Paris: IPH – ISIN: FR0010331421) (“Innate” or the “Company”), a French biotechnology company focused on discovering,...
Attis Provides an Update on Status of Nasdaq Listing
August 23, 2019 17:00 ET
|
Attis Industries, Inc.
Attis to Continue Appeal of Staff Determination Regarding Delinquent Reports MILTON, GA, Aug. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Attis Industries Inc. (NASDAQ: ATIS) (the “Company” or...
Attis Industries Reverse Splits Stock 1-for-8 to Maintain Nasdaq Listing
March 15, 2019 18:18 ET
|
Attis Industries, Inc.
MILTON, GA, March 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Attis Industries, Inc. (NASDAQ: ATIS) (the “Company” or “Attis”), a diversified innovation and technology holding company, today...